GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Early and Accurate Detection of Neurological Diseases: A Pursuit of Breakthrough Solutions
Early and accurate detection of neurological diseases remains one of the most pressing challenges in modern medicine. Neurodegenerative disorders like Alzheimer’s disease (AD), Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) often present with subtle symptoms in their initial stages, making early diagnosis difficult and delaying timely interventions. As our global population ages, the prevalence of these debilitating conditions is projected to rise dramatically, further emphasizing the urgent need for reliable diagnostic tools.
Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science
When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.
The Missing Link in Alzheimer’s: How a Natural Brain Element Could Be the Key to Reversing Memory Loss
For over thirty years, Bruce Yankner has been at the very forefront of Alzheimer's research. From his early days first proving the devastating toxicity of amyloid plaques in the 1990s, to his current work uncovering the brain's hidden reliance on natural lithium, his scientific journey has been nothing short of remarkable. By finally explaining the elusive missing link
Beyond Memory Loss: MRI Early Detection & 2026 Alzheimer's Advances
Groundbreaking 2026 research reveals structural brain changes precede amyloid plaques by 7+ years, transforming early detection, atypical Alzheimer's care, and targeted treatments.
Unlocking Clinical Equity: How Glassbury AI Meets FDA Diversity Action Plan Mandates in Alzheimer’s Research
Explore how Glassbury AI uses Google Cloud, MedGemma, and Vertex AI Explainable AI to guarantee FDA Diversity Action Plan compliance and accelerate Alzheimer's clinical trial matching.